Best Life Sciences Companies in Flanders, Belgium

Developer of optimized consortia therapeutics targeting inflammatory, CNS, and metabolic diseases. The company utilizes a proprietary platform to design and manufacture microbial therapeutics. Optimized consortia are developed through a bioinformatics-guided discovery engine. The company focuses on creating therapeutics with disease-modifying potential. Clinical programs include inflammatory bowel diseases, with preclinical programs in CNS and metabolic diseases. The company features end-to-end development capabilities, from discovery to clinical development.

Funding rounds

• Sep 2025Series B$64.1M
• Feb 2020Series B$15.1M

Founders & team

Sam PossemiersFounder & CEO

Investors

Ackermans & van Haaren, DuPont, Qbic Fund, MRM Technologies, Biocodex, BNP Paribas Fortis

Tech stack

BootstrapGoogle Font ApiIsotopeJplayerJqueryJquery Migrate

Developer of monoclonal antibody molecules for multiple disorders. The company has developed the monoclonal antibody molecules called agomAbs which stimulates the molecular and cellular repair mechanisms. It helps in organ function for patients suffering from fibrotic, inflammatory, autoimmune, and degenerative diseases.

Funding rounds

• Oct 2024Series D$89M
• Oct 2023Series C$100M
• Jul 2022Series B$40.5M
• Mar 2021Series B$74M

Founders & team

Tim KnotnerusCEO

Investors

Sanofi, Invus, Asabys Partners, Pfizer, Walleye, Redmile Group

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAmazon Web ServicesAosApple Icloud MailAzure

Provider of actinium-225 isotopes for targeted cancer therapy development and production. It focuses on enabling the widespread use of radiopharmaceuticals for personalized tumor treatment. The company aims to secure large-scale production of actinium-225, a promising alpha-emitting radioisotope. Its ultimate goal is to improve the accessibility of innovative cancer therapy based on actinium-225 and theranostics. The company supplies high-purity actinium-225 as an active product ingredient to the global pharmaceutical market.

Funding rounds

• Sep 2024Conventional Debt$37.3M
• Sep 2024Series A$102.6M

Founders & team

Sven BergheCEO

Investors

EQT, Kurma Partners, Eurazeo, Korys, PMV, Paladin Capital

Tech stack

AzureCookieyesCore-JsDropzoneGoogle AnalyticsHammer.Js

Aspect Analytics is the developer of mass spectroscopy integrated bioinformatics software for molecular imaging. Its services include bioinformatics, machine learning, AI and software engineering enables us to develop optimal data analysis strategies and MSI induces a true data deluge, requiring effective solutions for data management, storage, and analysis among others.

Funding rounds

• Sep 2025Series A$11.7M
• Dec 2019Grant (prize money)—

Founders & team

Marc ClaesenCo-Founder & CEOThomas MoermanCo-Founder & CTONico VerbeeckCo-Founder & COO

Investors

EIT Health, Capricorn Partners, PMV, HERAN Partners, Gemma Frisius Fund, KU Leuven

Tech stack

CloudflareCloudflare Bot ManagementCore-JsGoogle AnalyticsGoogle Font ApiGoogle Hosted Libraries

Developer of therapeutics for neuromuscular diseases. It offers a lead product small molecule inhibitors of HDAC6, a validated molecular target with strong biological rational for neuromuscular and neurodegenerative disorders, cardiometabolism, inflammatory and autoimmune diseases.

Funding rounds

• Mar 2025Series A$84.8M
• Jun 2024Series A$18.5M
• Dec 2019Seed$4.7M

Founders & team

Sylvain CelanireCEO

Investors

Asabys Partners, Lilly, Cmtrf, AdBio partners, V-Bio Ventures, PMV

Developer of technology for people with high light sensitivity and ocular disorders. The company has developed an active light management system, embedded inside a contact lens. It helps in the treatment of iris deficiencies, high order aberrations, light sensitivity, and photophobia.

Provider of a smart lamp for fall detection of elderly people. The lamp support caregivers in a residential care center to monitor elder's and resident's fall. The integrated device can monitor blood pressure and offers automated lighting when rising from the bed. The device can continuously measurements of room temperature or air quality. The features include fall prevention, night watch, air quality monitoring, smoke & CO2 detection, and care records for body vitals.

Funding rounds

• Jan 2025Series B$36.7M
• Jan 2022Series B$14.5M

Founders & team

Stijn VerreptCo-founder & CTORoeland PelgrimsChief Executive Officer

Investors

Life Sciences Partners, PMV, BNP Paribas Fortis, Angelini Ventures, Nexus NeuroTech Ventures, 15th Rock

Tech stack

Animate.CssApple Icloud MailBackdropCart FunctionalityCloudflareCloudflare Bot Management

Developer of molecular assays for the detection of various diseases. The company has developed its proprietary micro-technology platform that is based on integrated molecular and immunodiagnostics technology. It is used for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. It can also be used in the analysis of biomolecules associated with risk factors, early detection, staging, treatment selection, and monitoring of disease.

Provider of digital platform that utilizes artificial intelligence to streamline the search process for clinical trials. It offers an AI assistant for doctors and patients that seamlessly links patients with clinical trials, accelerating medical research, and enhancing patient care.

Funding rounds

• Sep 2025Seed$588.4K

Founders & team

Valerie VandeweerdCo-Founder & CEOSimeon DevosCo-Founder & CTO

Investors

Seeder Fund, LRM

Indigo is developing a needle-free continuous glucose monitoring technology using photonics technologies. Indigo is based in Ghent, Belgium, where it benefits from access to Ghent University and more specifically the Photonics Research Group and the NB-Photonics consortium.

Funding rounds

• Oct 2023Grant (prize money)$865.2K
• Jul 2020Series B$44.3M
• Jul 2018Grant (prize money)$2.9M
• Dec 2016Series A$7.3M

Founders & team

Danaë DelbekeCEO

Investors

Europa, Fund+, Ackermans & van Haaren, Imec, Capricorn Partners, Titansew

Tech stack

PhpApache Http ServerSectigo

Developer of mRNA-based immunotherapies for cancer and infectious diseases. It offers proprietary mRNA-based TriMix technology that has three mRNA molecules (caTLR4, CD40L, CD70) boost immune response through the dendritic cell pathway which has applications in indications of Melanoma and breast cancer.

Funding rounds

• Aug 2022Series B$38.9M
• Mar 2021Grant (prize money)$7.4M
• Feb 2021Grant (prize money)$6.2M
• Jun 2020Series B$38.2M

Founders & team

Kris ThielemansFounder & CSO

Investors

Europa, Life Sciences Partners, PMV, Fund+, Omega Funds, Boehringer Ingelheim Venture Fund

Developer of cell-based therapeutics. The company is developing extracellular vesicles and exosome drugs that can replace stem cell therapies. These extracellular vesicles are developed from mesenchymal stem cells. Extracellular vesicles function includes intracellular communication, transfer of proteins, lipids, and genetic material. These drugs are developed for inflammatory diseases, autoimmune diseases, and acute tissue injuries. These vesicles can also be used as a carrier for drug substances as they can transmit molecules between the cells and tissues.